Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. more
Time Frame | GILD | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.47% | -0.94% | -2.6% |
1-Month Return | 3.22% | -5.08% | -1.08% |
3-Month Return | 11.2% | -10.62% | 3.45% |
6-Month Return | 32.05% | -6.18% | 8.57% |
1-Year Return | 16.82% | 1.98% | 24.3% |
3-Year Return | 28.86% | -0.93% | 25.58% |
5-Year Return | 39.93% | 33.84% | 84.07% |
10-Year Return | 4.42% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 22.45B | 24.69B | 27.30B | 27.28B | 27.12B | [{"date":"2019-12-31","value":82.22,"profit":true},{"date":"2020-12-31","value":90.42,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.91,"profit":true},{"date":"2023-12-31","value":99.31,"profit":true}] |
Cost of Revenue | 4.67B | 4.57B | 6.60B | 5.66B | 5.80B | [{"date":"2019-12-31","value":70.82,"profit":true},{"date":"2020-12-31","value":69.26,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.7,"profit":true},{"date":"2023-12-31","value":87.93,"profit":true}] |
Gross Profit | 17.77B | 20.12B | 20.70B | 21.62B | 27.12B | [{"date":"2019-12-31","value":65.55,"profit":true},{"date":"2020-12-31","value":74.19,"profit":true},{"date":"2021-12-31","value":76.35,"profit":true},{"date":"2022-12-31","value":79.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 79.18% | 81.48% | 75.82% | 79.26% | 100.00% | [{"date":"2019-12-31","value":79.18,"profit":true},{"date":"2020-12-31","value":81.48,"profit":true},{"date":"2021-12-31","value":75.82,"profit":true},{"date":"2022-12-31","value":79.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 13.49B | 10.19B | 10.61B | 10.65B | 11.81B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":75.55,"profit":true},{"date":"2021-12-31","value":78.66,"profit":true},{"date":"2022-12-31","value":78.96,"profit":true},{"date":"2023-12-31","value":87.55,"profit":true}] |
Operating Income | 4.29B | 7.03B | 7.41B | 7.33B | 7.61B | [{"date":"2019-12-31","value":56.37,"profit":true},{"date":"2020-12-31","value":92.43,"profit":true},{"date":"2021-12-31","value":97.38,"profit":true},{"date":"2022-12-31","value":96.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (122.00M) | (3.39B) | (129.00M) | (2.45B) | (1.66B) | [{"date":"2019-12-31","value":-12200000000,"profit":false},{"date":"2020-12-31","value":-338600000000,"profit":false},{"date":"2021-12-31","value":-12900000000,"profit":false},{"date":"2022-12-31","value":-245100000000,"profit":false},{"date":"2023-12-31","value":-166400000000,"profit":false}] |
Pre-Tax Income | 5.16B | 1.67B | 8.28B | 5.81B | 6.86B | [{"date":"2019-12-31","value":62.33,"profit":true},{"date":"2020-12-31","value":20.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.23,"profit":true},{"date":"2023-12-31","value":82.86,"profit":true}] |
Income Taxes | (204.00M) | 1.58B | 2.08B | 1.25B | (1.25B) | [{"date":"2019-12-31","value":-9.82,"profit":false},{"date":"2020-12-31","value":76.07,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":60.09,"profit":true},{"date":"2023-12-31","value":-60.04,"profit":false}] |
Income After Taxes | 5.36B | 89.00M | 6.20B | 4.57B | 8.11B | [{"date":"2019-12-31","value":66.17,"profit":true},{"date":"2020-12-31","value":1.1,"profit":true},{"date":"2021-12-31","value":76.5,"profit":true},{"date":"2022-12-31","value":56.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | 5.36B | 89.00M | 6.20B | 4.57B | 5.83B | [{"date":"2019-12-31","value":86.5,"profit":true},{"date":"2020-12-31","value":1.44,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.63,"profit":true},{"date":"2023-12-31","value":94,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 5.39B | 89.00M | 6.22B | 4.59B | 5.67B | [{"date":"2019-12-31","value":86.52,"profit":true},{"date":"2020-12-31","value":1.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.77,"profit":true},{"date":"2023-12-31","value":91,"profit":true}] |
EPS (Diluted) | 6.63 | 7.09 | 7.29 | 7.27 | 7.04 | [{"date":"2019-12-31","value":90.95,"profit":true},{"date":"2020-12-31","value":97.26,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.73,"profit":true},{"date":"2023-12-31","value":96.57,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
GILD | |
---|---|
Cash Ratio | 0.43 |
Current Ratio | 1.26 |
Quick Ratio | 1.10 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GILD | |
---|---|
ROA (LTM) | 11.96% |
ROE (LTM) | 0.56% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GILD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.66 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.34 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GILD | |
---|---|
Trailing PE | 1028.56 |
Forward PE | 12.25 |
P/S (TTM) | 4.08 |
P/B | 6.24 |
Price/FCF | 28 |
EV/R | 4.72 |
EV/Ebitda | 34.09 |
PEG | 0.53 |
Gilead Sciences Inc (GILD) share price today is $93.4
Yes, Indians can buy shares of Gilead Sciences Inc (GILD) on Vested. To buy Gilead Sciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GILD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Gilead Sciences Inc (GILD) via the Vested app. You can start investing in Gilead Sciences Inc (GILD) with a minimum investment of $1.
You can invest in shares of Gilead Sciences Inc (GILD) via Vested in three simple steps:
The 52-week high price of Gilead Sciences Inc (GILD) is $98.08. The 52-week low price of Gilead Sciences Inc (GILD) is $60.24.
The price-to-earnings (P/E) ratio of Gilead Sciences Inc (GILD) is 1028.5555
The price-to-book (P/B) ratio of Gilead Sciences Inc (GILD) is 6.24
The dividend yield of Gilead Sciences Inc (GILD) is 3.33%
The market capitalization of Gilead Sciences Inc (GILD) is $115.37B
The stock symbol (or ticker) of Gilead Sciences Inc is GILD